Nanoform raises its mid-term business targets for 2025
Nanoform
Insider information
Nanoform raises its mid-term business targets for 2025
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows:
To nanoform annually at least 70 new active pharmaceutical ingredients, or ‘APIs’ (40% increase from the previous target of at least 50 new APIs annually)
To have in place 35 operating production lines, of which 7 to 14 are expected to be GMP compliant (40% increase from the previous target of 25 operating lines, of which 5-10 are GMP compliant)
To have 200-250 employees (0-25% increase from the previous target of ~200)
Copenhagen, June 2, 2021 - Nasdaq (Nasdaq: NDAQ) announces that trading in
MapsPeople A/S shares (short name: MAPS) will commence today on the Nasdaq
First North Premier Growth Market. MapsPeople belongs
Stockholm, June 1, 2021 - Nasdaq (Nasdaq: NDAQ) announces that trading in Cibus
Nordic Real Estate AB's shares (short name CIBUS) commence today on Nasdaq
Stockholm Main Market. The company belongs to
Investegate announcements from Media and Games Invest plc, Media and Games Invest; upgrade to the MSCI Germany Small Cap Index and completion of conversion from PLC to SE